12:00 AM
 | 
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

AAV1-FS344 regulatory update

Milo said FDA granted Orphan Drug designation to AAV1-FS344 to treat Becker and Duchenne muscular dystrophy....

Read the full 58 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >